Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bioline RX Ltd Sponsored ADR ( (BLRX) ) just unveiled an announcement.
On May 19, 2026, BioLineRx and Hemispherian reported new preclinical data for GLIX1, an orally administered, brain-penetrating TET2 pathway activator, showing robust anti-tumor activity in multiple glioblastoma models. The drug produced significant tumor growth inhibition and survival benefits in orthotopic xenograft studies, and in a temozolomide-resistant patient-derived xenograft model GLIX1 was effective where temozolomide showed no benefit.
The partners said the dose-dependent results strengthen the rationale for the ongoing Phase 1/2a trial of GLIX1 in recurrent and progressive glioblastoma and other high-grade gliomas, with further updates expected as the study progresses. The findings suggest GLIX1 could address a major unmet need in glioblastoma, particularly among patients who respond poorly to current temozolomide-based regimens, and may support broader development across DNA damage repair–dependent cancers.
The most recent analyst rating on (BLRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
The score is primarily held back by weak financial performance—especially the sharp 2025 revenue drop, ongoing losses, and negative free cash flow—despite improved cash burn and a still-positive equity base. Technicals are moderately supportive with the stock trading above key shorter-term moving averages, but mixed momentum signals and limited valuation support given negative earnings keep the overall score near the middle of the range.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical development-stage biopharmaceutical company focused on oncology and rare diseases, with shares listed on Nasdaq and TASE. Its lead pipeline asset is GLIX1, a first-in-class, oral small molecule targeting DNA damage response in glioblastoma and other solid tumors, developed in collaboration with Norway-based Hemispherian, while approved product APHEXDA (motixafortide) is marketed for stem cell mobilization in multiple myeloma.
Average Trading Volume: 18,642
Technical Sentiment Signal: Sell
Current Market Cap: $12.59M
See more data about BLRX stock on TipRanks’ Stock Analysis page.